Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Evaluation of HMB Supplementation on Motor Performance in Sarcopenic Patients
Authors not listed
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · 2025
Cellular senescence
Chronic inflammation
Exercise
Human
Systematic review
Randomized controlled trial
Review
Abstract
Aging is often accompanied by the reduction and weakening of muscle mass, a condition defined as sarcopenia. According to the most recent criteria from the European Working Group on Sarcopenia in Older People, sarcopenia is considered probable when low muscle strength is documented in the patient. The diagnosis of sarcopenia is then confirmed by the presence of reduced muscle mass quantity or quality; it is classified as severe when low muscle strength, reduced muscle quantity and quality, and poor physical performance are all present. According to a recent systematic review of 130 studies, sarcopenia is estimated to affect 10-16% of older adults worldwide. Low muscle strength and rapid atrophy may also result from prolonged immobility, which is an undesirable consequence of hospitalization after illness or injury.
Approximately 65% of elderly patients experience reduced ambulatory function due to hospitalization, and between 30% and 55% report a decline in daily living activities. It has been reported that healthy older adults lose 1 kg (approximately 6%) of lean tissue in the lower limbs after 10 days of bed rest, with a corresponding 16% decline in isokinetic strength of the knee extensors. Muscle atrophy during bed rest is primarily attributed to a marked decrease in skeletal muscle protein synthesis rates, although an accelerated rate of muscle protein degradation compared to synthesis cannot be ruled out. The onset of sarcopenia is further promoted by inflammation, immunosenescence, anabolic resistance, and increased oxidative stress.
Since proper diet, physical activity, and supplementation are currently considered the fundamental pillars for the treatment and prevention of sarcopenia, the identification of a specific food for special medical purposes (AFMS) capable of slowing the progression of sarcopenia is extremely important. Treating sarcopenia also means preventing the associated negative outcomes, including lower overall and progression-free survival rates, postoperative complications, extended hospital stays in patients with various medical conditions, as well as falls and fractures, metabolic disorders, cognitive decline, and mortality in the general population.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-29 MST
Cite this
APA
Anonymous. (2025). Evaluation of HMB Supplementation on Motor Performance in Sarcopenic Patients. <em>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</em>. https://clinicaltrials.gov/study/NCT06801808
Vancouver
Anonymous. Evaluation of HMB Supplementation on Motor Performance in Sarcopenic Patients. Fondazione Policlinico Universitario Agostino Gemelli IRCCS. 2025.
BibTeX
@misc{anon2025Evalua,
title = {Evaluation of HMB Supplementation on Motor Performance in Sarcopenic Patients},
author = {Anonymous},
journal = {Fondazione Policlinico Universitario Agostino Gemelli IRCCS},
year = {2025},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Scientific reports 2026
Citation only
Systematic review and meta-analysis of the effects of exercise in older adults with sarcopenia.
Kirsehir Ahi Evran Universitesi 2025
Open access · US-GOV
Investigation of Respiratory Muscle Sarcopenia in Geriatric Individuals
PubMed 2008
Preprint
Aging and sarcopenia.
Clinical Interventions in Aging 2018
Open access · CC-BY
Sarcopenia: assessment of disease burden and strategies to improve outcomes
Odense University Hospital 2023
Open access · US-GOV
Impact of Acute Hospitalisation and Resistance Training on Muscle Architecture and Physical Performance in Older Adults
Medicina (Kaunas, Lithuania) 2026
Citation only